B cells in the treatment of indolent lymphoma

By | April 15, 2012

B cell indolent lymphoma including follicular lymphoma, B cell chronic lymphocytic leukemia mortar; small lymphocytic lymphoma (SSL), lymphatic plasma cell lymphoma and splenic marginal zone B cell lymphoma. The slow growth rate of the clinical features, peripheral blood and bone marrow is frequently involved, the majority of patients when treatment was III / VI period. A variety of radiotherapy and chemotherapy although you can control the disease, but it is difficult to cure, easy to relapse, and more and more physicians recognize that, for the treatment of indolent lymphoma B cells to alleviate symptoms only treatment is ineffective for patients to be progressive adopt a more aggressive treatment strategies. Includes the following measures:
1. A-interferon is a recombinant human -interferon can induce a low-grade malignant lymphoma, particularly follicular lymphoma remission of biological agents. So far, a lot of evidence that B cell indolent lymphoma treated with interferon is effective, but also benefit Central class of drugs with combined can significantly prolong survival in patients.
2. Stem cell support for high-dose chemotherapy previously reported, patients with autologous transplantation can induce remission, but with longer follow-up period, relapse rate increase, some patients with secondary myelodysplastic syndrome. Disease recurrence may be related to infusion of stem cells containing the relevant lymphoma cells. With the improvement of bone marrow purification technology, the recurrence rate may be reduced.
3. Chatter Yin Ling nuclear hard core glanced back new analogues analogues including fludarabine, 2 back and a spray of chlorine oxygen gland statins, is a lymphatic toxicity of anti-metabolic drugs, and its inert NHL, especially in LL and follicular NHL in the inhibition of resting and dividing cells significantly. Ridge recently cast a glance analogues has been gradually extended from the salvage treatment as first-line drug therapy.
4. Allogeneic bone marrow transplantation-related mortality in allogeneic transplant as high as 30%, so only a small part of the B cell indolent lymphoma patients receiving allogeneic bone marrow transplantation. Early in the disease, most patients receive autologous bone marrow transplantation. In recent years, fludarabine were included in the conditioning regimen, with cyclophosphamide discretion glue, busulfan, Ara back, melphalan, 200cGy-TBI and anti-thymocyte globulin (ATG) combined with, can reduce the transplant-related disease incidence and mortality, reduce graft-versus-host disease incidence and severity, so that elderly patients or those with other diseases who received allogeneic transplants possible.
5. Monoclonal antibody therapy at present, for the NHL tumor cells have different antigen monoclonal antibody treatment for NHL. Which is the single most widely used monoclonal antibodies and radiolabeled monoclonal antibodies. U.S. FDA has approved rituximab treatment of recurrent low-grade or follicular NHL, which marks the monoclonal antibody therapy has made milestone progress.

Leave a Reply

Your email address will not be published. Required fields are marked *